×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CTXR – citius pharmaceuticals, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CTXR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/11
02:33 pm
ctxr
Citius Pharmaceuticals (CTXR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $6.00 price target on the stock.
Medium
Report
Citius Pharmaceuticals (CTXR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $6.00 price target on the stock.
3/6
03:17 pm
ctxr
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR [Yahoo! Finance]
Low
Report
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR [Yahoo! Finance]
2/24
08:00 am
ctxr
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Medium
Report
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
2/13
08:27 am
ctxr
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ [Yahoo! Finance]
High
Report
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ [Yahoo! Finance]
2/13
08:00 am
ctxr
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
High
Report
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
12/23
05:16 pm
ctxr
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
12/23
04:30 pm
ctxr
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
High
Report
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Date
Time
Symbol
Company Name
Action
%Chg
5/14/2025
04:30 pm
ctxr
citius pharmaceuticals, inc.
BEAT
Report
-7.1%
citius pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/10
09:04 am
ctxr
Form 8-K Citius Pharmaceuticals, For: Mar 10
Medium
Report
Form 8-K Citius Pharmaceuticals, For: Mar 10
3/4
09:25 am
ctxr
Form 8-K Citius Pharmaceuticals, For: Mar 04
Medium
Report
Form 8-K Citius Pharmaceuticals, For: Mar 04
2/24
08:04 am
ctxr
Form ARS Citius Pharmaceuticals, For: Sep 30
Medium
Report
Form ARS Citius Pharmaceuticals, For: Sep 30
2/24
08:02 am
ctxr
Form DEFA14A Citius Pharmaceuticals,
Medium
Report
Form DEFA14A Citius Pharmaceuticals,
2/24
08:01 am
ctxr
Form DEF 14A Citius Pharmaceuticals, For: Apr 06
High
Report
Form DEF 14A Citius Pharmaceuticals, For: Apr 06
2/17
02:47 pm
ctxr
Form SCHEDULE 13G/A Citius Pharmaceuticals, Filed by: CVI Investments, Inc.
Low
Report
Form SCHEDULE 13G/A Citius Pharmaceuticals, Filed by: CVI Investments, Inc.
2/13
08:30 am
ctxr
Form 8-K Citius Pharmaceuticals, For: Feb 09
High
Report
Form 8-K Citius Pharmaceuticals, For: Feb 09
2/13
08:01 am
ctxr
Form 10-Q Citius Pharmaceuticals, For: Dec 31
Medium
Report
Form 10-Q Citius Pharmaceuticals, For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/10
Form 4 Citius Pharmaceuticals, For: Oct 08 Filed by: Dutia Suren G
26.8%
4/1 Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 22.4%
4/28 Form 8-K Citius Pharmaceuticals, For: Apr 27 19.2%
10/15 Citius Pharmaceuticals to Present at the MicroCap Rodeo 14.1%
1/22 Form 8-K Citius Pharmaceuticals, For: Jan 22 13.0%
12/20 Form DEFA14A Citius Pharmaceuticals, 9.4%
2/13 Form 10-Q Citius Pharmaceuticals, For: Dec 31 8.9%
9/20 Citius Pharma -9.5% after filing to offer units [Seeking Alpha] 8.4%
5/15 Form 10-Q Citius Pharmaceuticals, For: Mar 31 7.6%
4/24 Form 424B3 Citius Pharmaceuticals, 7.5%
4/1 Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 22.4%
4/28 Form 8-K Citius Pharmaceuticals, For: Apr 27 19.2%
10/15 Citius Pharmaceuticals to Present at the MicroCap Rodeo 14.1%
1/22 Form 8-K Citius Pharmaceuticals, For: Jan 22 13.0%
12/20 Form DEFA14A Citius Pharmaceuticals, 9.4%
2/13 Form 10-Q Citius Pharmaceuticals, For: Dec 31 8.9%
9/20 Citius Pharma -9.5% after filing to offer units [Seeking Alpha] 8.4%
5/15 Form 10-Q Citius Pharmaceuticals, For: Mar 31 7.6%
4/24 Form 424B3 Citius Pharmaceuticals, 7.5%
TOP News Decliners
2/14
Form 8-K Citius Pharmaceuticals, For: Feb 14
-16.9%
9/23 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -14.4%
4/29 Form 8-K Citius Pharmaceuticals, For: Apr 29 -12.4%
1/25 Citius Pharmaceuticals Inc (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock. -10.3%
9/4 Form 8-K Citius Pharmaceuticals, For: Sep 04 -9.6%
3/4 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
9/9 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.2%
4/3 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.0%
2/3 Form 8-K Citius Pharmaceuticals, For: Jan 31 -7.6%
2/4 Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial -6.7%
9/23 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -14.4%
4/29 Form 8-K Citius Pharmaceuticals, For: Apr 29 -12.4%
1/25 Citius Pharmaceuticals Inc (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock. -10.3%
9/4 Form 8-K Citius Pharmaceuticals, For: Sep 04 -9.6%
3/4 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
9/9 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.2%
4/3 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.0%
2/3 Form 8-K Citius Pharmaceuticals, For: Jan 31 -7.6%
2/4 Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial -6.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: